Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673802 · ClinicalTrials.gov registry record · Early Phase 1
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
A Early Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT01673802 is a Early Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 18 participants.
The verdict
NCT01673802, a Early Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this project is to evaluate the role of gadoxetate (Eovist®) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma. This pilot project aims to address a long-term pitfall in the imaging of cholangiocarcinomas, by providing higher resolution delineation of these often infiltrative tumors on single-source, Dual-Energy Spectral Multi Detector CT (MDCT), capitalizing on improved spatial resolution achievable with MDCT compared to MRI and at the same time producing a non-invasive CT cholangiogram to aid in accurate diagnosis and treatment planning of cholangiocarcinoma, particularly, the hilar variety.
Interventions
- DRUG CT scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673802
The ClinicalTrials.gov registry entry for NCT01673802 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CT scan is the first listed.
NCT01673802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673802 about?
NCT01673802 is a clinical study titled "The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma". The purpose of this project is to evaluate the role of gadoxetate (Eovist®) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma. This pilot project aims to address a long-term pitfall in the imaging of cholangiocarcinomas, by providing higher resolution delineation of these oft...
What is the current status of trial NCT01673802?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2012-08. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01673802?
The interventions under investigation include: CT scan (DRUG).
Who is sponsoring clinical trial NCT01673802?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.